The role of the patent system and declining US obesity rates following GLP-1 drug distribution
- 1The obesity rate among US adults reached 36.4% this year.
- 2The current GLP-1 medication usage rate of 1 in 9 adults represents a 10-fold increase in the proportion of adults taking GLP-1 since 2022.
- 3Generic manufacturers supplied Ozempic and Wegovy generics to the market in India at prices under $14 per month earlier this year.
So what's the key point?
The number of people taking obesity treatments has grown significantly, with 1 in 9 US adults now using them. This increase is due to the availability of more affordable generic versions of the drugs.
Source Fortune · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.